Louw EH, et al. - The association of residual renal function (RRF) with erythropoietin-stimulating agents (ESA) dose requirements in end-stage kidney disease (ESKD) patients receiving chronic dialysis was investigated in this study. Findings demonstrated that irrespective of dialysis modality, renin-angiotensin-system blocker use, primary renal disease or hyperparathyroidism, RRF was not associated with ESA dose requirements.